If you’re having robotic prostate surgery, you may wonder whether you’ll need hormone therapy first. For most men, conventional hormone therapy is not routinely given before radical prostatectomy. Earlier studies found that it could shrink the prostate and reduce positive surgical margins, but did not establish that it improved long-term cancer outcomes.
Newer studies are exploring stronger hormone treatments given before and after surgery, with promising results in some high-risk patients. However, this doesn’t mean you’ll automatically need hormone therapy before surgery. Your specialist will recommend a treatment plan based on your cancer risk and individual circumstances.
What Does “Neoadjuvant Hormone Therapy” Mean?
If your doctor mentions neoadjuvant hormone therapy, it means you receive hormonal treatment before prostate surgery. The aim may be to shrink your prostate, reduce the amount of cancer present or target cancer cells that might exist beyond the prostate. Whether this improves your long-term outcome depends on the treatment used and the available evidence.
You may also hear “adjuvant” (treatment after surgery) or “perioperative” (treatment before and after surgery). These terms matter because studies such as PROTEUS looked at treatment around surgery, not just beforehand. So, ask your specialist exactly which treatment is being considered for you and when you would receive it.
Hormone Therapy Around Prostate Surgery: What Do the Terms Mean?
| Term | When treatment is given | What current evidence means |
| Neoadjuvant | Before surgery | Older ADT studies improved some pathological outcomes but did not establish long-term benefit |
| Adjuvant | After surgery | NICE does not recommend adjuvant hormone therapy after prostatectomy outside a clinical trial |
| Perioperative | Before and after surgery | Strategy tested in PROTEUS |
| ADT alone before surgery | Before prostatectomy only | Not established as routine standard surgical care |
| ADT + apalutamide perioperatively | Before and after surgery | PROTEUS showed improved MFS versus perioperative ADT alone in selected high-risk disease |
| ADT with radiotherapy | Before, during and/or after radiotherapy | Established treatment for appropriate higher-risk disease |
Why Was Hormone Therapy Considered Before Prostate Surgery?
If you’re planning prostate surgery, you might wonder whether hormone therapy beforehand could help. Prostate cancer often relies on testosterone to grow, so lowering your testosterone levels may help shrink your prostate and the cancer.
Doctors hoped this would make it easier to remove the cancer and reduce the chance of leaving cancer cells behind. However, earlier studies didn’t clearly show that this approach lowered the risk of your cancer returning later.
Did Older Hormone Therapy Trials Shrink the Prostate Before Surgery?

Yes. If you have hormone therapy before prostate surgery, it can shrink your prostate and lower your PSA levels. Earlier studies also found that some men had fewer cancer cells at the edges of the removed prostate, particularly after longer treatment.
You might think this means your surgery will be more successful, but shrinking the cancer doesn’t guarantee a better long-term result. Doctors still need to consider whether the treatment actually reduces your risk of the cancer returning, and older studies didn’t clearly prove that it did.
What Is a Positive Surgical Margin and Why Did Researchers Focus on It?
After your prostate is removed, a pathologist examines the tissue to see whether cancer cells reach an inked surgical edge. This is called a positive surgical margin. It can suggest a greater risk of cancer remaining or returning, but it does not prove that cancer cells have been left behind or that recurrence will occur.
You might expect hormone therapy before surgery to improve your chances because it can reduce positive margins. However, this doesn’t guarantee that your cancer is less likely to return or spread. Your long-term health is what matters most.
Why Didn’t Better Surgical Margins Lead to Better Long-Term Outcomes?
You might assume that if your surgeon finds fewer cancer cells at the edges of your removed prostate, your cancer is less likely to return. However, cancer cells may have already spread beyond the prostate before surgery, and hormone therapy may not get rid of them.
Even if hormone therapy reduces the likelihood of a positive margin, it does not guarantee that your cancer will stay controlled after surgery. Earlier randomised studies did not establish a clear improvement in recurrence-free or overall survival from conventional neoadjuvant ADT. Your doctor therefore needs to assess the expected benefits of the particular regimen being considered.
Is Hormone Therapy Routinely Recommended Before Radical Prostatectomy?
If you’re planning radical prostate surgery, you usually won’t need hormone therapy beforehand. Earlier studies didn’t show clear long-term benefits, so it hasn’t become a routine part of surgery for prostate cancer.
Hormone therapy is, however, commonly combined with radiotherapy for certain patients. So, if your doctor recommends it before surgery, ask why it’s being considered for you and what benefits they expect based on your cancer and treatment plan.
UK Guidance Note
Current NICE guidance recommends radical prostatectomy or radical radiotherapy for appropriate CPG 4 and 5 localised or locally advanced prostate cancer. NICE clearly recommends androgen deprivation therapy alongside radical radiotherapy for CPG 2–5 disease.
NICE NG131 does not currently recommend perioperative apalutamide plus ADT as routine treatment around radical prostatectomy. Although PROTEUS reported improved outcomes in selected high-risk patients, this does not automatically make the regimen standard NHS care. Your specialist should explain the current recommendations, treatment availability and whether the evidence applies to your cancer.
Why Is Hormone Therapy Common Before Radiotherapy but Not Surgery?

If you’re wondering why some men receive hormone therapy before radiotherapy while others go straight to prostate surgery, it comes down to the evidence. For certain men, combining hormone therapy with radiotherapy has been shown to improve cancer outcomes. However, older studies didn’t show the same clear benefit when hormone therapy was given before surgery.
So, if your treatment plan looks different from someone else’s, don’t assume something is wrong. Your doctor considers your cancer risk, the treatment you’ve chosen and the evidence for that approach when recommending what’s right for you.
Why Are Researchers Revisiting Neoadjuvant Treatment Now?
If you are considering surgery, you may wonder why researchers are again studying hormone therapy before an operation. Earlier treatments improved some pathological findings without clearly improving long-term outcomes. Researchers are revisiting this approach because several things have changed:
- More potent androgen-receptor treatments are available: Medicines such as apalutamide block androgen signalling more intensively than older approaches.
- High-risk patients can be selected more carefully: Modern imaging, pathology and risk classification help identify people with a greater risk of recurrence.
- Trials can target microscopic disease: Systemic therapy may potentially treat cancer cells beyond the visible prostate before or after surgery.
- Pathological response can be measured: Researchers can examine how much viable tumour remains in the removed prostate.
- Long-term endpoints are now being studied: Newer trials assess biochemical recurrence, metastasis-free survival and other clinically meaningful outcomes.
- Perioperative strategies are being tested: Some modern trials give treatment both before and after surgery rather than only before it.
For you, the important question is not simply whether hormone therapy shrinks your prostate, but whether treatment around your surgery improves outcomes that matter to your future health.
What Have Trials of Apalutamide and Other Intensive Hormone Treatments Found?
If you’re preparing for prostate surgery, you may wonder whether stronger hormone treatments could control your cancer more effectively. Studies of intensified androgen-receptor treatment, particularly apalutamide combined with ADT, have reported encouraging pathological responses. Other medicines, including darolutamide, are also being investigated, but their evidence should not be assumed to be identical.
Although no treatment guarantees that your cancer will not return, PROTEUS has shown a metastasis-free survival benefit from adding apalutamide to ADT before and after surgery in selected high-risk patients. Whether other drugs or treatment only before surgery offer the same benefit remains uncertain.
Did the ARNEO Trial Show That Better Pathology Prevents Recurrence?
If you’re wondering whether hormone therapy before prostate surgery can stop your cancer from returning, the ARNEO trial provides some encouraging but limited results. Adding apalutamide to degarelix helped reduce the amount of cancer remaining in the prostate before surgery, and fewer men experienced a rise in PSA during follow-up. However, the trial was relatively small, so these findings need careful interpretation.
Although these results are encouraging, they don’t guarantee that your cancer won’t return. The difference in PSA recurrence between treatment groups wasn’t statistically significant, so you shouldn’t assume that better pathological results after surgery will necessarily lead to lasting benefits. More research is needed to confirm the long-term advantages before this specific treatment approach can be routinely recommended for men like you.
Evidence Note
The final ARNEO analysis had a median follow-up of 54 months. Three-year biochemical recurrence occurred in 24% of men receiving degarelix plus apalutamide and 39% receiving degarelix plus placebo, but the difference was not statistically significant. Biochemical recurrence-free survival was also not significantly different between treatment groups.
Interestingly, organ-confined or specimen-confined disease was associated with better subsequent outcomes, whereas achieving minimal residual disease itself was not predictive of better biochemical recurrence-free survival. The trial was powered for its pathological primary endpoint rather than these longer-term secondary outcomes.
What Has the 2026 PROTEUS Trial Changed?

If you have high-risk prostate cancer, you may wonder whether adding stronger hormone treatment around surgery could reduce the risk of your cancer spreading. In the 2026 PROTEUS trial, five-year metastasis-free survival was 78.2% with apalutamide plus ADT compared with 73.5% with ADT alone a difference of 4.7 percentage points.
You also need to weigh the benefit against side effects. Severe or medically significant grade 3–4 adverse events occurred in 39.6% of patients receiving apalutamide plus ADT, compared with 31.0% receiving ADT alone. Because treatment was given before and after surgery, these results do not prove that hormone therapy given only before your operation would provide the same benefit.
Research Insight
PROTEUS enrolled 2,109 patients with newly diagnosed high-risk localised or locally advanced prostate cancer. Participants received perioperative ADT plus either apalutamide or placebo for six months before and six months after radical prostatectomy.
At five years, metastasis-free survival was 78.2% with apalutamide plus ADT versus 73.5% with ADT plus placebo, with a hazard ratio of 0.80. Pathological complete response or minimal residual disease was also more common with apalutamide, at 8.9% versus 1.0%.
Does PROTEUS Mean Everyone Should Have Hormone Therapy Before Surgery?
If you’re having prostate surgery, you might wonder whether the PROTEUS results mean you should have hormone therapy first. Not necessarily. The trial focused on men with high-risk or locally advanced prostate cancer, so the findings may not apply to you if your cancer is low-risk.
You also need to consider the extra side effects and the fact that treatment was given before and after surgery. Although the results are promising, hormone therapy before surgery isn’t automatically right for everyone. Your specialist can explain whether this approach may benefit you and whether it’s recommended for your particular cancer.
Clinical Note
Both PROTEUS groups received ADT before and after radical prostatectomy. Apalutamide was added to ADT in the experimental group.
This means the trial established an advantage for adding apalutamide to a perioperative ADT backbone in the studied high-risk population. It should not be described as proof that a conventional short course of ADT before prostatectomy alone improves metastasis-free survival.
What Are the Downsides of Taking Hormone Therapy Before Surgery?
If you’re considering hormone therapy before prostate surgery, it’s important to understand how it could affect you. Lower testosterone can cause hot flushes, tiredness, reduced sex drive, erection problems and changes in muscle strength or mood. Stronger treatments may also cause additional side effects, including skin rashes.
You may also find that your testosterone takes months to recover after treatment stops. So, before deciding, speak to your specialist about whether the potential benefits for your cancer outweigh these side effects, particularly if your cancer isn’t considered high-risk.
When Might Hormone Therapy Be Given Before Robotic Prostatectomy?

If you have high-risk prostate cancer, your specialist may discuss whether intensive hormone treatment before and after surgery is appropriate in light of newer research and current treatment availability. However, a large prostate or raised PSA alone does not establish that you will benefit from neoadjuvant treatment. Your overall cancer stage, grade, risk category and treatment options are also important.
If you’re considering robotic prostate surgery, ask your surgeon whether your cancer matches the patients who benefited in recent trials and whether this treatment is suitable and available to you. Your decision should balance the potential benefits against side effects, based on your individual cancer risk and treatment plan.
Myth vs Fact
| Myth | Fact |
| Everyone having robotic prostatectomy should now receive hormone therapy first. | PROTEUS studied a selected high-risk population and used treatment both before and after surgery. |
| A smaller prostate means the cancer is less likely to return. | Prostate shrinkage and better pathological findings do not automatically prove long-term benefit. |
| Fewer positive margins guarantee cure. | Margin status affects recurrence risk but does not determine outcome by itself. |
| PROTEUS proved ordinary pre-operative ADT works. | PROTEUS tested apalutamide added to perioperative ADT, not pre-operative ADT alone. |
| PROTEUS compared hormone therapy with surgery alone. | Both trial groups received perioperative ADT. |
| Hormone therapy is used the same way with radiotherapy and surgery. | ADT with radiotherapy has an established role; perioperative therapy around surgery is a newer strategy. |
| A high PSA alone means you need hormone therapy before surgery. | Treatment selection depends on the full risk profile, not PSA alone. |
| Positive phase 3 data automatically means the treatment is routine in the UK. | Guidance, licensing, funding and local pathways still determine clinical availability. |
Key Takeaways
- Neoadjuvant hormone therapy means treatment before prostate surgery.
- Perioperative treatment means therapy is given both before and after surgery.
- Older neoadjuvant ADT reduced prostate size and positive-margin rates but did not clearly establish better long-term outcomes.
- Robotic surgery itself does not determine whether hormone therapy is appropriate; cancer risk features do.
- ARNEO improved pathological responses but did not show a statistically significant difference in biochemical recurrence outcomes in its final analysis.
- PROTEUS enrolled 2,109 high-risk patients and showed improved five-year metastasis-free survival with apalutamide plus perioperative ADT.
Frequently Asked Questions
1. Is hormone therapy routinely given before robotic prostate surgery?
No, hormone therapy is not routinely recommended before radical prostatectomy because older studies did not clearly demonstrate better long-term cancer outcomes. Your specialist will consider your individual cancer risk when planning treatment.
2. What is neoadjuvant hormone therapy for prostate cancer?
Neoadjuvant hormone therapy means receiving hormone treatment before prostate surgery. It aims to reduce testosterone, shrink the prostate and control the cancer before the operation.
3. Can hormone therapy shrink the prostate before surgery?
Yes, hormone therapy can shrink the prostate and lower PSA levels before surgery. However, a smaller prostate or fewer cancer cells at the surgical margins does not guarantee better long-term outcomes.
4. What is a positive surgical margin after prostate surgery?
A positive surgical margin means cancer cells are present at the edge of the removed prostate. It may increase the risk of recurrence, but it does not necessarily mean your cancer will return.
5. Why is hormone therapy used before radiotherapy but not routinely before surgery?
For certain patients, hormone therapy combined with radiotherapy has been shown to improve cancer outcomes. Older studies did not demonstrate the same clear long-term benefit when hormone therapy was given before prostate surgery.
6. Can apalutamide or darolutamide help before prostate surgery?
Apalutamide plus ADT improved outcomes in the 2026 PROTEUS trial involving selected high-risk patients receiving treatment before and after surgery. Darolutamide and other intensified approaches are also being studied, but you should not assume that results from apalutamide apply equally to every medicine or treatment schedule.
7. What did the ARNEO trial find about hormone therapy before surgery?
The ARNEO trial found that adding apalutamide improved the amount of cancer reduction seen in the prostate after treatment. However, the difference in PSA outcomes was not statistically significant, so a lasting benefit was not conclusively established.
8. What did the 2026 PROTEUS trial show?
The 2026 PROTEUS trial found that adding apalutamide to ADT before and after surgery improved five-year metastasis-free survival from 73.5% to 78.2%. The findings relate to treatment around surgery in men with high-risk or locally advanced prostate cancer, not hormone therapy before surgery alone.
9. What are the side effects of hormone therapy before prostate surgery?
Possible side effects include hot flushes, tiredness, reduced sex drive, erection difficulties, mood changes and reduced muscle strength. Some treatments may also cause skin rashes, and testosterone recovery can take months after treatment ends.
10. Who might be considered for hormone therapy around prostate surgery?
Your specialist may discuss treatment around surgery if you have high-risk or locally advanced prostate cancer. Your cancer characteristics, potential benefits, side effects and the latest evidence will help determine whether this approach is suitable for you.
Final Thoughts: Hormone Therapy Before Robotic Prostate Surgery
Hormone therapy is not routinely given before robotic prostate surgery because older studies did not show clear long-term benefits. However, newer research, including the PROTEUS trial, suggests that intensive hormone treatment given before and after surgery may benefit some men with high-risk prostate cancer. If you’re considering surgery, speak to your specialist about whether this approach is suitable for your cancer, the potential benefits and the possible side effects.
If you’re considering robotic prostate surgery and want to understand whether hormone therapy might be relevant to your treatment, contact Prostate Clinic London for specialist advice about your cancer risk, treatment options and a personalised consultation.
References:
- National Institute for Health and Care Excellence (2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Available at: https://www.nice.org.uk/guidance/ng131
- Nayak, A.L. et al. (2021) ‘Do androgen-directed therapies improve outcomes in prostate cancer patients undergoing radical prostatectomy? A systematic review and meta-analysis’, Canadian Urological Association Journal, 15(8), pp. 269–279. Available at: https://pubmed.ncbi.nlm.nih.gov/33443481/
- Katayama, S. et al. (2022) ‘Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis’, Scandinavian Journal of Urology, 56(2), pp. 85–93. Available at: https://pubmed.ncbi.nlm.nih.gov/35142251/
- Devos, G. et al. (2023) ‘ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer’, European Urology, 83(6), pp. 508–518. Available at: https://pubmed.ncbi.nlm.nih.gov/36167599/
- Giesen, A. et al. (2026) ‘Final Results of the Randomised Phase 2 Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer (ARNEO)’, European Urology Oncology, 9(3), pp. 598–610. Available at: https://pubmed.ncbi.nlm.nih.gov/41469270/
- Taplin, M.E. et al. (2026) ‘Perioperative Apalutamide in High-Risk Localized Prostate Cancer’, New England Journal of Medicine, 395(6), pp. 546–560. Available at: https://pubmed.ncbi.nlm.nih.gov/42223077/